ADAP is down after merging with TCRR, while TCRR is up. The merger dilutes ADAP, but in return, it gets one year of additional cash and the TCRR pipeline for free. The merger looks like a smart deal ...
Pre-market open on 3/20/25, Adaptimmune (NASDAQ:ADAP) provided a business update for 4Q24 (in lieu of financial results for the quarter/full year to be released in conjunction with the company’s 10-K ...
Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort We performed a retrospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results